Drug maker Indivior (INDV.L) has announced plans to delist its shares from the London Stock Exchange (LSE), marking the ...

Piper Sandler analyst David Amsellem reiterated a Buy rating on Indivior (INDV – Research Report) today and set a price target of $13.00. The company’s shares opened today at ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on Indivior (INDV – Research Report). The company’s shares opened today at p988.50. C ...

As it works to send opioid use disorder (OUD) treatment Sublocade back into its prior growth territory, Indivior is switching ...

Indivior PLC - Richmond, Virginia-based maker of medicines to treat substance use - Non-Executive Director Joe Ciaffoni buys 56,000 shares at USD8.96, worth USD501,519, on Thursday. Indivior on ...

Indivior PLC (Nasdaq/LSE: INDV) today announced the appointment of Patrick Barry as Chief Commercial Officer, effective June 2. In this role, Barry will lead the company's commercial growth strategy, ...

Drugmaker Indivior has announced plans to cancel its secondary listing in London, just a year after moving its primary ...

(Reuters) -Pharma firm Indivior said on Monday it will cancel its secondary listing on the London Stock Exchange, effective July 25, maintaining its primary listing on the Nasdaq to reduce costs and ...